TP53 and neoplasm: Whilst HPV-positive tumours rarely harbour TP53 mutations (2–3% of cases [16]), the importance of the HPV E6 oncoprotein in targeting p53 for proteasomal degradation in HPV oncogenesis [17,18], invites scrutiny of metabolism in HPV-positive disease, particularly given the dearth of previously published data.